Evaluation of [131I]I- and [177Lu]Lu-DTPA-A11 Minibody for Radioimmunotherapy in a Preclinical Model of PSCA-Expressing Prostate Cancer.

Wen-Ting K TsaiKirstin A ZettlitzMagnus DahlbomRobert E ReiterAnna M Wu

Published in: Molecular imaging and biology (2021)

These findings show the potential of the anti-PSCA minibody for targeted radioimmunotherapy with minimal toxicity, and the application of immunoPET and dosimetry for personalized treatment.

Keyphrases

prostate cancer
radical prostatectomy
oxidative stress
cancer therapy
cell therapy
stem cells
risk assessment
drug delivery
human health
monte carlo